Navigation Links
BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
Date:4/10/2008

- Strategic Collaboration with the National Cancer Institute's NABTT

Consortium -

BRISBANE, Calif., April 10 /PRNewswire/ -- BiPar Sciences, Inc. today announced the expansion of the clinical program for the company's lead product candidate, BSI-201, into glioblastoma multiforme (GBM), the most common glioma in adults. BSI-201, the first poly ADP-ribose polymerase (PARP) inhibitor in BiPar's DNA repair portfolio, crosses the blood-brain barrier, a unique property that enables its targeted investigation in the brain tumor setting. This study is being conducted by investigators from the New Approaches to Brain Tumor Therapy (NABTT) consortium, a National Cancer Institute-funded research group. In addition to GBM, BiPar is currently enrolling BSI-201 in a randomized Phase 2 trial for triple-negative breast cancer and is initiating Phase 2 trials in uterine and BRCA-negative ovarian cancers.

"We believe a multi-drug strategy is the best approach to battling GBM. There is a significant need for new treatments that can offer GBM patients and their families additional hope," said Stuart A. Grossman, M.D., professor of oncology, medicine and neurological surgery at Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital and the co-chairperson for this study.

"BSI-201 is a promising agent that has been well tolerated in combination with cytotoxic therapies in patients with solid tumors and potentially addresses a key pathway by which GBM cells resist the effects of existing medications. We are hopeful that BSI-201 will safely potentiate the power of current therapies for GBM and improve survival in this difficult-to-treat cancer," said Jaishri Blakeley, M.D., Assistant Professor of Neurology, Oncology and Neurosurgery at Johns Hopkins and the study chairperson for this study.

"The scientific observations that BSI-201 crosses the blood-brain barrier and has a mechanistic basis to synergize with t
'/>"/>

SOURCE BiPar Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
2. BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
3. BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
4. BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
5. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
6. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
7. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
8. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
9. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , Aug. 27, 2015  Eli Lilly and Company ... Global Healthcare Conference on Thursday, September 17, 2015. ... of Lilly Oncology and Richard Gaynor , M.D., ... for Lilly Oncology, will participate in a fireside chat ... A live audio webcast will be available on the ...
(Date:8/27/2015)... 27, 2015  A mere one in seven new ... Hamilton . A new white paper from ... impeding and disrupting manufacturers, success. The white ... Value In Product Development Processes provides insight into: ... how it affects the product development process resulting in: ...
(Date:8/27/2015)... and TORONTO , Aug. 27, 2015 ... today announced the issuance of a white paper on ... insulin spray product.  The white paper was presented to ... stockholders by Dr. James H. Anderson, Jr. , ... may be viewed online on the Generex website. ...
Breaking Medicine Technology:Lilly to Participate in Morgan Stanley Global Healthcare Conference 2New White Paper Reveals How Manufacturers Can Improve Product Development Processes 2Generex Announces Issuance of Buccal Insulin White Paper 2Generex Announces Issuance of Buccal Insulin White Paper 3Generex Announces Issuance of Buccal Insulin White Paper 4
... Calif., March 24 NuRx,Pharmaceuticals, Inc. (OTC Bulletin Board: ... a Phase I clinical trial of the first-in-class,rexinoid receptor ... expects to complete in the fourth,quarter of this year, ... compound. NRX4204 is the company,s first drug candidate in ...
... March 22 Issue of The Lancet -, ... announced that efficacy results of the randomized ... the March 22 issue of The Lancet ... in,combination with 5-fluorouracil/leucovorin (5-FU/LV), a chemotherapy,regimen called ...
Cached Medicine Technology:NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204 2Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases 2Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases 3Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases 4Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases 5
(Date:8/27/2015)... ... August 27, 2015 , ... King Kullen, America’s First ... Founded by Michael J. Cullen in 1930 and recognized by the Smithsonian Institute as ... Still family owned and operated, the Cullen & Kennedy families have created a culture ...
(Date:8/27/2015)... ... August 27, 2015 , ... Since its launch on ... having twelve offices in three counties, LA, Orange and San Bernardino. Their ... Founded by Dr. Richy Agajanian, the Oncology Institute of Hope and Innovation ...
(Date:8/27/2015)... ... 27, 2015 , ... Catalent Pharma Solutions, the leading global ... health products, today announced that Ms. Esther Sadler-Williams, Global Director Strategic Development and ... Radisson Blu Edwardian Hotel, London Heathrow, on September 9th – 10th, 2015. , ...
(Date:8/27/2015)... ... ... "I need a little help supporting and stabilizing myself when getting into ... "I developed this support handle to give me the extra little boost that I ... a helping hand when stepping into or out of the tub or shower. The ...
(Date:8/27/2015)... CT (PRWEB) , ... August 27, 2015 , ... ... devices, announces today that they have launched their new corporate website http://www.Z-Medica.com ... site compliments a product-focused website that was launched last year. , “We ...
Breaking Medicine News(10 mins):Health News:King Kullen Honors Their 85 Years of Success this August 2Health News:California’s Largest Private Oncology Practice Serves 50,000 Patients in 8 years 2Health News:Clinical Trial Supply Chain Logistics to be Discussed By Catalent Expert at Upcoming Flypharma Conference 2Health News:Inventor and InventHelp Client Develops Bathroom Stabilization Aid (LCC-432) 2Health News:Z-Medica® Launches New Corporate Website 2
... March 4 STAAR Surgical,Company (Nasdaq: STAA ... invasive ophthalmic products, congratulates Dr. Brian Boxer,Wachler on ... this morning,correcting NBCSports.com columnist Alan Abrahamson,s vision with ... the only foldable, minimally invasive lens approved,in the ...
... schools participate in 6th annual KID,HEALTHY--Steps to Healthy ... To combat the,rising trend of childhood obesity ... fifth grade students and parents from Los Angeles,Orange, ... schools and,after-school programs will participate in the KID ...
... acute kidney injury (AKI), an external device containing human ... significantly reduces the risk of death, according to a ... the American Society of Nephrology. , The experimental renal ... desperately ill patients with AKI. "Deployment of the ...
... Argosy Publishing, an award-winning interactive, visual content ... www.visiblebody.com ), the first free, Web-based 3-D interactive ... developed for educators, and health and medical professionals, ... that demonstrates how the human body works. It ...
... Spring Forward - it,s National Sleep Awareness Week, ... physician and,providers at Swedish Medical Center have transitioned ... Sleep Medicine Associates. The new medical group,founded by ... Swedish,Sleep Medicine Institute, will initially operate two centers ...
... the Wildlife Conservation Society, the BioDiversity Research Institute, ... environmental mercurymuch of which comes from human-generated emissionsis ... common loons in the Northeast. , The ... symbolic of northern lakes and wildernessappear in the ...
Cached Medicine News:Health News:STAAR Surgical's Visian ICL Procedure Performed Live on NBC's Today show 2Health News:STAAR Surgical's Visian ICL Procedure Performed Live on NBC's Today show 3Health News:Southern California Parents and Kids Take Healthy Steps in Tackling Childhood Obesity 2Health News:Southern California Parents and Kids Take Healthy Steps in Tackling Childhood Obesity 3Health News:'Renal Assist Device' reduces risk of death from acute kidney failure 2Health News:Argosy publishing launches The Visible Body 2Health News:Argosy publishing launches The Visible Body 3Health News:Sleep Medicine Associates Opens New Doors at Swedish - Cherry Hill Campus 2Health News:Scientists find mercury threatens next generation of loons 2
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
Inquire...
For use with Snap-In Snap-Out-II tip inserts. Available in five styles, the Snap-In Snap-Out-II Laparoscopic Instrument Handles offer the broadest range available....
Inquire...
Medicine Products: